PD-L1 expression in Congolese women with triple negative breast cancer

Abstract

Introduction: Inhibition of antibody interaction against Programmed Death-Ligand 1 (PD-L1) is becoming a valuable therapeutic strategy in the management of breast cancer (BC). The expression of PD-L1 in Congolese patients with metastatic triple-negative breast cancer (TNBC) has never been reported. Methods: We investigated PD-L1 expression in a series of Congolese patients diagnosed with TNBC. Immunohistochemical analyzes were performed using anti-PD-L1 antibodies. Results: In this study, the expression of PD-L1 in samples of patients with TNBC in Kinshasa (Democratic Republic of the Congo) was evaluated. Appropriate tissue samples were available from 14 patients with TNBC. Tumor sections incorporated in paraffin were stained with the PD-L1 antibody. The PD-L1 positive expression rate in TNBC was 71.43% (10/14). Conclusion: This study quantified the expression of PD-L1 in TNBC for the first time in a Congolese cohort. This opens the possibility of explor